CD274 and small cell lung carcinoma: In the Impower133 trial, patients with the EMT-like SCLC-I subtype showed significantly improved OS when treated with a combination of chemotherapy and the PD-L1 monoclonal antibody atezolizumab, compared to other subtypes (8).